7:18 PM
 | 
Nov 19, 2013
 |  BC Extra  |  Company News

FDA panel backs BioMarin's Vimizim

FDA's Endocrinologic and Metabolic Drugs Advisory Committee backed approval of Vimizim elosulfase alfa from BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to treat mucopolysaccharidosis IVA (MPS-IVA, Morquio's syndrome)....

Read the full 112 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >